| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Rauchenzauner, M Laimer, M Wiedmann, A Tschoner, K Salzmann, W Sturm, A Sandhofer, G Walser, G Luef, C F Ebenbichle. The novel insulin resistance parameters RBP4 and GLP-1 in patients treated with valproic acid: just a sidestep? Epilepsy research. vol 104. issue 3. 2013-11-14. PMID:23182413. |
in summary, the absence of any relationship with rbp4 and glp-1 concentrations does not suggest a role of these novel insulin resistance parameters as potential regulators of glucose and fat metabolism during vpa-therapy. |
2013-11-14 |
2023-08-12 |
Not clear |
| Junpeng Yang, Jianmin Ren, Jun Song, Fuqiang Liu, Chuanlong Wu, Xuping Wang, Lei Gong, Wenjuan Li, Fang Xiao, Fei Yan, Xinguo Hou, Li Che. Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes. International journal of molecular medicine. vol 31. issue 6. 2013-11-12. PMID:23588664. |
glucagon-like peptide 1 (glp-1), a gut-derived peptide, has been reported to have profound effects on metabolism and to reduce insulin resistance. |
2013-11-12 |
2023-08-12 |
Not clear |
| Noriyuki Higuchi, Tohru Hira, Nao Yamada, Hiroshi Har. Oral administration of corn zein hydrolysate stimulates GLP-1 and GIP secretion and improves glucose tolerance in male normal rats and Goto-Kakizaki rats. Endocrinology. vol 154. issue 9. 2013-11-12. PMID:23798598. |
blood samples were collected from the tail vein or by using the jugular catheter to measure glucose, insulin, glp-1, and gip levels. |
2013-11-12 |
2023-08-12 |
rat |
| Karen L Teff, Michael R Rickels, Joanna Grudziak, Carissa Fuller, Huong-Lan Nguyen, Karl Rickel. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. vol 62. issue 9. 2013-11-12. PMID:23835329. |
we found that olanzapine, an aap highly associated with weight gain, causes significant elevations in postprandial insulin, glucagon-like peptide 1 (glp-1), and glucagon coincident with insulin resistance compared with placebo. |
2013-11-12 |
2023-08-12 |
human |
| G C Hall, A D McMahon, M-P Dain, E Wang, P D Hom. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabetic medicine : a journal of the British Diabetic Association. vol 30. issue 6. 2013-11-04. PMID:23330649. |
primary-care observational database study of the efficacy of glp-1 receptor agonists and insulin in the uk. |
2013-11-04 |
2023-08-12 |
Not clear |
| Seung-Lark Hwang, Okyun Kwon, Sun-Gyun Kim, In-Kyu Lee, Yong Deuk Ki. B-cell translocation gene 2 positively regulates GLP-1-stimulated insulin secretion via induction of PDX-1 in pancreatic β-cells. Experimental & molecular medicine. vol 45. 2013-10-25. PMID:23703573. |
glp-1 treatment significantly increased btg2, pdx-1 and insulin gene expression in pancreatic β-cells. |
2013-10-25 |
2023-08-12 |
Not clear |
| Seung-Lark Hwang, Okyun Kwon, Sun-Gyun Kim, In-Kyu Lee, Yong Deuk Ki. B-cell translocation gene 2 positively regulates GLP-1-stimulated insulin secretion via induction of PDX-1 in pancreatic β-cells. Experimental & molecular medicine. vol 45. 2013-10-25. PMID:23703573. |
exendin-4 (ex-4), a glp-1 agonist, and glp-1 in pancreatic β-cells increased insulin secretion through the btg2-pdx-1-insulin pathway, which was blocked by endogenous btg2 knockdown using a btg2 small interfering rna knockdown system. |
2013-10-25 |
2023-08-12 |
Not clear |
| Seung-Lark Hwang, Okyun Kwon, Sun-Gyun Kim, In-Kyu Lee, Yong Deuk Ki. B-cell translocation gene 2 positively regulates GLP-1-stimulated insulin secretion via induction of PDX-1 in pancreatic β-cells. Experimental & molecular medicine. vol 45. 2013-10-25. PMID:23703573. |
finally, we revealed that ex-4 and glp-1 significantly elevated insulin secretion via upregulation of the btg2-pdx-1 axis in pancreatic islets, and this phenomenon was abolished by endogenous btg2 knockdown. |
2013-10-25 |
2023-08-12 |
Not clear |
| Seung-Lark Hwang, Okyun Kwon, Sun-Gyun Kim, In-Kyu Lee, Yong Deuk Ki. B-cell translocation gene 2 positively regulates GLP-1-stimulated insulin secretion via induction of PDX-1 in pancreatic β-cells. Experimental & molecular medicine. vol 45. 2013-10-25. PMID:23703573. |
collectively, our current study provides a novel molecular mechanism by which glp-1 positively regulates insulin gene expression via btg2, suggesting that btg2 has a key function in insulin secretion in pancreatic β-cells. |
2013-10-25 |
2023-08-12 |
Not clear |
| Tae Jung Oh, Ji Yon Shin, Gyeong Hoon Kang, Kyong Soo Park, Young Min Ch. Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats. Experimental & molecular medicine. vol 45. 2013-10-25. PMID:23827952. |
during the intraperitoneal glucose tolerance tests with the injection of a glp-1 analog, metformin and/or fenofibrate did not alter the insulin secretory responses. |
2013-10-25 |
2023-08-12 |
rat |
| M Bomba, D Ciavardelli, E Silvestri, L M T Canzoniero, R Lattanzio, P Chiappini, M Piantelli, C Di Ilio, A Consoli, S L Sens. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell death & disease. vol 4. 2013-10-23. PMID:23640454. |
glucagone like peptide-1 (glp-1) is an incretin hormone and, like glp-1 analogs, stimulates insulin secretion and has been employed in the treatment of t2dm. |
2013-10-23 |
2023-08-12 |
mouse |
| Amalia Gastaldelli, Michael A Nauck, Raffaella Balen. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. Metabolism: clinical and experimental. vol 62. issue 9. 2013-10-23. PMID:23831441. |
eight weeks of treatment with long-acting glp-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. |
2013-10-23 |
2023-08-12 |
human |
| Daniel A de Luis, Rocio Aller, Rosa Conde, David Primo, Olatz Izaola, Maria Jose Castro, Manuel Gonzalez Sagrad. Basal glucagonlike peptide 1 levels and metabolic syndrome in obese patients. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. vol 60. issue 6. 2013-10-22. PMID:22534628. |
glucagonlike peptide 1 (glp-1) is the most potent stimulator of glucose-induced insulin secretion. |
2013-10-22 |
2023-08-12 |
Not clear |
| Yoshiki Kusunoki, Tomoyuki Katsuno, Makiko Myojin, Kana Miyakoshi, Takashi Ikawa, Toshihiro Matsuo, Fumihiro Ochi, Masaru Tokuda, Kazuki Murai, Masayuki Miuchi, Tomoya Hamaguchi, Jun-ichiro Miyagawa, Mitsuyoshi Namb. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocrine journal. vol 60. issue 4. 2013-10-22. PMID:23220949. |
in addition, a meal tolerance test was conducted to monitor changes in insulin secretion and active glp-1 and total gip values. |
2013-10-22 |
2023-08-12 |
human |
| Li-Nong Ji, Ju-Ming Lu, Xiao-Hui Guo, Wen-Ying Yang, Jian-Ping Weng, Wei-Ping Jia, Da-Jin Zou, Zhi-Guang Zhou, De-Min Yu, Jie Liu, Zhong-Yan Shan, Yu-Zhi Yang, Ren-Ming Hu, Da-Long Zhu, Li-Yong Yang, Li Chen, Zhi-Gang Zhao, Qi-Fu Li, Hao-Ming Tian, Qiu-He Ji, Jing Liu, Jia-Pu Ge, Li-Xin Shi, Yan-Cheng X. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC public health. vol 13. 2013-10-22. PMID:23800082. |
we assessed the efficacy of oral antidiabetes drugs (oads), glucagon-like peptide-1 (glp-1) receptor agonists, and insulin for treatment of t2dm across multiple regions in china. |
2013-10-22 |
2023-08-12 |
Not clear |
| J Vora, S C Bain, T Damci, G Dzida, P Hollander, L F Meneghini, S A Ros. Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes. Diabetes & metabolism. vol 39. issue 1. 2013-10-21. PMID:23022130. |
both drug classes reduce blood glucose through physiological pathways mediated by the glp-1 receptor, resulting in glucose-dependent enhancement of residual insulin secretion and inhibition of glucagon secretion. |
2013-10-21 |
2023-08-12 |
Not clear |
| Berthold Hocher, Christoph Reichetzeder, Markus L Alte. Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research. Kidney & blood pressure research. vol 36. issue 1. 2013-10-17. PMID:22947920. |
glp-1 stimulates glucose-dependent insulin secretion from pancreatic beta-cells and suppresses glucagon release from alpha-cells, thereby improving glucose control. |
2013-10-17 |
2023-08-12 |
Not clear |
| Alison R Meloni, Mary Beth DeYoung, Jenny Han, Jennie H Best, Michael Grim. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Cardiovascular diabetology. vol 12. 2013-10-17. PMID:23522121. |
this retrospective analysis calculated the absolute benefit increase (abi) of using exenatide once weekly (qw), a glucagon-like peptide-1 (glp-1) receptor agonist, vs an oral glucose-lowering medication or insulin glargine to achieve ada-recommended goals. |
2013-10-17 |
2023-08-12 |
Not clear |
| Makoto Nishizawa, Hajime Nakabayashi, Keigo Uehara, Atsushi Nakagawa, Kenzo Uchida, Daisuke Koy. Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways. American journal of physiology. Endocrinology and metabolism. vol 305. issue 3. 2013-10-17. PMID:23715725. |
intraportal glp-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways. |
2013-10-17 |
2023-08-12 |
rat |
| Makoto Nishizawa, Hajime Nakabayashi, Keigo Uehara, Atsushi Nakagawa, Kenzo Uchida, Daisuke Koy. Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways. American journal of physiology. Endocrinology and metabolism. vol 305. issue 3. 2013-10-17. PMID:23715725. |
to determine whether the glp-1-induced vagal pathways lead to a neuronal-mediated component (nmc) of insulin secretion, we infused glp-1 at a physiological or pharmacological dose (1 or 3 pmol·kg(-1)·min(-1), respectively) into the portal vein in conscious rats with selective hepatic vagotomy (vagox) or sham operation (sham). |
2013-10-17 |
2023-08-12 |
rat |